<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284827</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV 2017-08</org_study_id>
    <nct_id>NCT03284827</nct_id>
  </id_info>
  <brief_title>Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement</brief_title>
  <acronym>ADAPT-TAVR</acronym>
  <official_title>a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duk-Woo Park, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs.
      dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac
      CT imaging) and cerebral embolization (documented with brainDiffusion-weighted (DW) magnetic
      resonance (MR) imaging) in patients without an absolute indication for chronic oral
      anticoagulation (OAC) after successful transcatheter aortic valve replacement(TAVR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>an incidence of leaflet thrombosis</measure>
    <time_frame>6-month</time_frame>
    <description>an incidence of leaflet thrombosis on four-dimensional, volume-rendered cardiac CT imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6-month</time_frame>
    <description>all-cause, cardiovascular, or non-cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or transient ischemic attack</measure>
    <time_frame>6-month</time_frame>
    <description>disabling or non-disabling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event</measure>
    <time_frame>6-month</time_frame>
    <description>life-threatening or disabling, major bleeding, or minor bleeding according to VARC(The Valve Academic Research Consortium)-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Echocardiographic parameter</measure>
    <time_frame>6-month</time_frame>
    <description>the mean transaortic valve pressure gradient and velocity time integral ratio at baseline and 6-month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New lesion volume on MRI scans</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of neurological and neurocognitive function</measure>
    <time_frame>6-month</time_frame>
    <description>according to NeuroARC(Neuro Academic Research Consortium) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of new lesions on brain DW-MRI scans</measure>
    <time_frame>6-month</time_frame>
    <description>the number of new lesions on brain DW-MRI scans at 6 months relative to immediate post-TAVR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOAC</intervention_name>
    <description>edoxaban (60 mg once daily [OD]) for at least 6 months</description>
    <arm_group_label>NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAPT</intervention_name>
    <description>clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months</description>
    <arm_group_label>DAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older with successful TAVR procedure* (either native valve
             or valve-in-valve) with any approved/marketed device.

               -  A successful TAVR is defined as device success according to the VARC-2 criteria:

                    1. correct positioning of a single prosthetic heart valve into the proper
                       anatomical location AND

                    2. Intended performance of the prosthetic heart valve (no prosthesis- patient
                       mismatch* and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s,
                       no moderate or severe prosthetic valve regurgitation AND

                    3. absence of periprocedural complications (any type of stroke,
                       life-threatening bleeding, acute coronary artery obstruction requiring
                       intervention, major vascular complication requiring intervention, unresolved
                       acute valve thrombosis, or any requirement of a repeat procedure.

          2. The patient or guardian agrees to the study protocol and the schedule of clinical
             follow-up, and provides informed, written consent, as approved by the appropriate
             Institutional Review Board/Ethical Committee of the respective clinical site.

        Exclusion Criteria:

          1. Any atrial fibrillation with an indication for chronic OAC.

          2. An ongoing indication for OAC or any other indication for continued treatment with any
             OAC

          3. Any ongoing indication for DAPT (recent acute coronary syndrome or PCI(percutaneous
             coronary intervention) within 12 months)

          4. Planned coronary or vascular intervention or major surgery

          5. Known bleeding diathesis (i.e., active bleeding, hemoglobin level &lt;8.5% or platelet
             count â‰¤ 50,000/mm3, history of cerebral bleeding, or major surgery within 30 days)

          6. Clinically overt stroke within the last 3 months

          7. Moderate and severe hepatic impairment, and any hepatic disease associated with
             coagulopathy

          8. Severe renal impairment (estimated glomerular filtration rate &lt;30 mL/min per 1.73 m2),
             chronic dialysis, or post-TAVR unresolved acute kidney injury

          9. Terminal illness with life expectancy &lt;6 months

         10. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-jung Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, Asan Medical Center Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duk-woo Park, MD</last_name>
    <phone>82230103995</phone>
    <email>dwpark@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duk-woo Park, MD</last_name>
      <email>dwpark@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Duk-woo Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Woo Park, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>edoxaban</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>cerebral embolization</keyword>
  <keyword>leaflet thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

